PMDI Stock Overview
Engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Psychemedics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$3.93 |
| 52 Week Low | US$1.11 |
| Beta | 0.67 |
| 1 Month Change | -16.24% |
| 3 Month Change | -15.52% |
| 1 Year Change | -31.47% |
| 3 Year Change | -72.85% |
| 5 Year Change | -78.97% |
| Change since IPO | -81.65% |
Recent News & Updates
Recent updates
Psychemedics Corporation's (NASDAQ:PMD) Shares Climb 37% But Its Business Is Yet to Catch Up
Dec 07
Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares
Jul 29There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump
Jan 08Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07
May 13Psychemedics GAAP EPS of -$0.06, revenue of $6.51M
Aug 09Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play
Apr 25Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend
Nov 18Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target
Oct 18Psychemedics reports Q1 results
May 10We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope
May 07Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt
Mar 05Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)
Jan 30How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?
Jan 11Psychemedics reports Q3 results
Nov 09Shareholder Returns
| PMDI | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -22.8% | -8.8% | 0.04% |
| 1Y | -31.5% | -9.2% | 27.3% |
Return vs Industry: PMDI underperformed the US Healthcare industry which returned -6.4% over the past year.
Return vs Market: PMDI underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| PMDI volatility | |
|---|---|
| PMDI Average Weekly Movement | 16.4% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PMDI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PMDI's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 116 | Brian Hullinger | www.psychemedics.com |
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company’s testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.
Psychemedics Corporation Fundamentals Summary
| PMDI fundamental statistics | |
|---|---|
| Market cap | US$10.02m |
| Earnings (TTM) | -US$2.99m |
| Revenue (TTM) | US$20.26m |
0.6x
P/S Ratio-3.9x
P/E RatioIs PMDI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMDI income statement (TTM) | |
|---|---|
| Revenue | US$20.26m |
| Cost of Revenue | US$12.49m |
| Gross Profit | US$7.77m |
| Other Expenses | US$10.77m |
| Earnings | -US$2.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 38.36% |
| Net Profit Margin | -14.78% |
| Debt/Equity Ratio | 9.1% |
How did PMDI perform over the long term?
See historical performance and comparison